Niruriside
Niruriside is a HIV REV/RRE complex inhibitor. Niruriside specifically inhibits the binding interaction between HIV REV protein and RRE RNA, with an IC50 of 3.3 μM, and shows no significant activity against the unrelated R17 capsid protein/operator RNA binding system. At the tested concentrations, Niruriside fails to protect CEM-SS cells from acute HIV-1 infection. Niruriside can be used in the research of human immunodeficiency virus (HIV) infection.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 173268-90-1
- Fòrmula: C38H42O17
- Peso molecular:770.73
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
Actividad biológica
Descripciòn
In Vitro
Niruriside (260 μM; 6 days post-infection, plus 4 h XTT incubation) does not protect CEM-SS cells from acute HIV-1 RF infection at concentrations up to 260 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:CEM-SS cells infected with HIV-1 RF
-
Concentration:260 μM
-
Incubation Time:6 days post-infection, plus 4 h XTT incubation
-
Result:Did not protect CEM-SS cells from acute HIV-1 infection at concentrations.
Chemical Information
-
No. CAS 173268-90-1
-
Peso molecular 770.73
-
Fòrmula C38H42O17
-
SMILES
O=C(O[C@@H]1[C@@H](O)[C@H](COC(/C=C/C2=CC=CC=C2)=O)O[C@@]1(O[C@@H]3[C@H](OC(C)=O)[C@@H](O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O3)COC(C)=O)/C=C/C4=CC=CC=C4
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocolo
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Co-Immunoprecipitation
Co-immunoprecipitation technology can verify protein interaction based on the specific immune reaction between antibodies and antigens.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)